AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular
- Novel JEL™ Technology for Periocular Administration
COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) - AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 trial with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME). “We have achieved a major milestone, full enrollment in our Phase 1, Safety Trial in the U.S.” said Diane Tang-Liu, PhD, CEO, President & Co-Founder of AiViva Biopharma. “AIV007 (lenvatinib) is a broad-spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation. We believe AIV007, formulated with our proprietary JEL™ technology and administered periocularly, has the potential to address the root causes of wet AMD, DME and many other ocular diseases. We are on target to have the study completed, and full results Q1 2025.”
This Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who have received a single periocular injection of AIV007 and will undergo monthly evaluation for up to 6 months to assess safety, tolerability, biological activity, and the reduction of treatment burden.
About Age-Related Macular Degeneration and Diabetic Macular Edema
AMD is a progressive retinal disease that is the leading cause of blindness in adults over the age of 60, affecting up to 15 million U.S. people. AMD affects the macular, center portion of the retina, that is responsible for central vision and color perception. In patients with wet AMD vision loss is caused by abnormal blood vessels leaking fluid and blood into and beneath the retina. Diabetic macular edema is manifested as retinal thickening and swelling caused by accumulation of intraretinal fluid usually due to blood sugar levels being consistently high. If untreated, chronic macular edema can lead to irreversible damage of the macula and permanent vision loss.
About AiViva Biopharma, Inc.
AiViva is a clinical stage biotech company led by a team of seasoned industry experts with proven track record in drug development and commercialization. AiViva has developed innovative approaches to address high unmet medical needs through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis. Core competencies include development of novel drugs using proprietary technologies, including JEL™, in specialty therapeutic areas of ophthalmology, dermatology, urology and oncology. Please visit www.aiviva.com to learn more.
Contact:
AiViva Biopharma
office@aiviva.com
- 魔方眼科技携手央美打造线上艺术盛宴,开启远程观展新时代
- 孙建东‖大雅正声--当代中国画学术中坚六十家提名展
- 供应链责任:如何通过BSCI验厂审核强化企业形象
- 悠纯真零酸奶来袭!权威营养师力荐,引领健康新潮流
- 江西银行广州分行携手幸福金龄会 打造“新江银 心服务”广州市中老年文化艺术节
- Corpay Cross-Border被指定为AEG Presents UK在欧洲的官方B2B外汇合作伙伴
- 香港旅发局与小红书达成战略合作意向 推动文旅行业高质量发展
- Talkdesk聘请Simon Horrocks担任亚太地区负责人,推动公司在人工智能创新领域实现区域性增长
- 5000w48v转500v540v550v升压电源变换器
- Wipro与Nokia联合推出5G专用无线解决方案,加速企业数字化转型
- 惊艳亮相2024AWE,MQ名气定义厨房新实用主义潮流
- 与明星张桐一起探厂!海信中央空调品质“大考”看直播找答案~福利送不停
- Aritco瑞特科米兰设计周演绎北欧童话
- 浪潮海岳大模型亮相2024全国企业家活动日暨中国企业家年会
- 罗永浩锐评老板超薄油烟机:高颜值,省空间、吸力大、噪音小
- 退休人员取得在职时的工资薪金所得,个人所得税如何处理 ?
- Moody’s宣布参与守护者计划(Project Guardian),探索资产代币化
- MWC 2024速递丨押宝AI,产业巨头激战未来
- 2024年度中国百强艺术家榜单——高旨军作品鉴赏
- 贝尔金推出未来商业部门,深入产品创新并创建新类别
- 泰康在粤机构协同参加第13届中国(广州)国际金融交易·博览会
- Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Secon
- 老板电器成立首家专注AI烹饪技术的子公司,加速烹饪大模型研发
- 平安产险安徽分公司:“党建共建聚合力,乡村振兴谋新篇”乡风文明100行动落地大通区孔店乡河沿村
- L&T Technology Services、ISG和CNBC TV18推出数字工程奖
- 芯原携最新的高效能IP应用亮相2024年国际嵌入式展
- 首届中美可持续发展峰会在加州圆满举行,引领国际绿色发展新方向
- 818无烟厨房日 看火星人集成灶14年解决油烟问题的执着与坚持
- Bringing confident diagnosis to more patients at low cost: Philips launches new AI-enabled CT 5300 a
- Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
推荐
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯